Omega-3 Fatty Acid Treatment, With or Without Cytidine, Fails to Show Therapeutic Properties in Bipolar Disorder
| Autor: | Suzann M. Babb, Andrew L. Stoll, Caitlin Ravichandran, Beth L. Murphy, Bruce M. Cohen, William A. Carlezon, Peter Q. Harris |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Bipolar Disorder Global Assessment of Functioning Cytidine Pharmacology Placebo Gastroenterology law.invention Double-Blind Method Randomized controlled trial law Internal medicine Fatty Acids Omega-3 medicine Humans Pharmacology (medical) Treatment Failure Bipolar disorder Omega 3 fatty acid business.industry Middle Aged medicine.disease Clinical trial Psychiatry and Mental health Mood Drug Therapy Combination Female medicine.symptom business Mania |
| Zdroj: | Journal of Clinical Psychopharmacology. 32:699-703 |
| ISSN: | 0271-0749 |
| DOI: | 10.1097/jcp.0b013e318266854c |
| Popis: | Objective This study aimed to test the effects of omega-3 fatty acids (O3FA), given as fish oil capsules, with and without oral cytidine (CYT), a pyrimidine with reported preclinical and clinical antidepressant-like effects, in patients with bipolar disorder (BD). Methods A total of 45 outpatients with diagnosed BD (type I) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition - Text Revision, were recruited for this 4-month, randomized, double-blind, placebo-controlled, add-on study. Treatment groups were (1) oral CYT + O3FA, (2) placebo + O3FA, and (3) placebo + placebo control. O3FA was given 2 g twice a day and CYT was administered as 1 g twice a day. Results There was no statistically significant difference among the groups in the primary outcome: study retention. Clinical measures improved in all treatment groups, and there were no significant differences between groups, including change in probability of symptoms of depression or mania, change in positive ratings of depression or mania, or change in Global Assessment of Functioning scores. Neither CYT + O3FA nor placebo + O3FA treatment was superior to placebo treatment. Rather, there was a statistically nonsignificant trend for both groups treated with O3FA to do worse than the placebo group. Conclusions Despite preclinical studies suggesting that the effect of O3FA might be augmented with pyrimidines, add-on CYT did not substantially improve mood symptoms in BD. In addition, although a power analysis indicated that the sample size would be adequate to see beneficial effects similar to those previously reported, O3FA treatment by itself was not superior to placebo for BD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|